Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Cunha-Vaz J, Ashton P, Iezzi R, Campochiaro P, Dugel PU, Holz FG et al. Sustained delivery fluocinolone acetonide vitreous implants: long-term benefit in patients with chronic diabetic macular edema. Ophthalmology 2014; 121 (10): 1892–1903.
Rahimy E, Shahlaee A, Khan MA, Ying GS, Maguire JI, Ho AC et al. Conversion to aflibercept after prior anti-VEGF therapy for persistent diabetic macular edema. Am J Ophthalmol 2016; 164: 118–127.
Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology 2016; 123 (6): 1351–1359.
Wells JA, Glassman AR, Jampol LM, Aiello LP, Antoszyk AN, Baker CW et al. Association of baseline visual acuity and retinal thickness with 1-year efficacy of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema. JAMA Ophthalmol 2016; 134 (2): 127–134.
Wood EH, Karth PA, Moshfeghi DM, Leng T . Short-term outcomes of aflibercept therapy for diabetic macular edema in patients with incomplete response to ranibizumab and/or bevacizumab. Ophthalmic Surg Lasers Imaging Retina 2015; 46 (9): 950–954.
Shah CP, Heier JS . Aflibercept for diabetic macular edema in eyes previously treated with ranibizumab and/or bevacizumab may further improve macular thickness. Ophthalmic Surg Lasers Imaging Retina 2016; 47 (9): 836–839.
Lazzeri S, Ripandelli G, Sartini MS, Parravano M, Varano M, Nardi M et al. Aflibercept administration in neovascular age-related macular degeneration refractory to previous anti-vascular endothelial growth factor drugs: a critical review and new possible approaches to move forward. Angiogenesis 2015; 18 (4): 397–432.
Zhioua I, Semoun O, Lalloum F, Souied EH . Intravitreal dexamethasone implant in patients with ranibizumab persistent diabetic macular edema. Retina 2015; 35 (7): 1429–1435.
Totan Y, Guler E, Guragac FB . Dexamethasone intravitreal implant for chronic diabetic macular edema resistant to intravitreal bevacizumab treatment. Curr Eye Res 2016; 41 (1): 107–113.
Lazic R, Lukic M, Boras I, Draca N, Vlasic M, Gabric N et al. Treatment of anti-vascular endothelial growth factor-resistant diabetic macular edema with dexamethasone intravitreal implant. Retina 2014; 34 (4): 719–724.
Bansal P, Gupta V, Gupta A, Dogra MR, Ram J . Efficacy of Ozurdex implant in recalcitrant diabetic macular edema- a single-center experience. Int Ophthalmol 2015; 36 (2): 207–216.
Gutierrez-Benitez L, Millan E, Arias L, Garcia P, Cobos E, Caminal M . Dexamethasone intravitreal implants for diabetic macular edema refractory to ranibizumab monotherapy or combination therapy. Arch Soc Esp Oftalmol 2015; 90 (10): 475–480.
Alshahrani ST, Dolz-Marco R, Gallego-Pinazo R, Diaz-Llopis M, Arevalo JF . Intravitreal dexamethasone implant for the treatment of refractory macular edema in retinal vascular diseases: results of the KKESH International Collaborative Retina Study Group. Retina 2016; 36 (1): 131–136.
Maturi RK, Bleau L, Saunders J, Mubasher M, Stewart MW . A 12-month, single-masked, randomized controlled study of eyes with persistent diabetic macular edema after multiple anti-vegf injections to assess the efficacy of the dexamethasone-delayed delivery system as an adjunct to bevacizumab compared with continued bevacizumab monotherapy. Retina 2015; 35 (8): 1604–1614.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Ashraf, M., Souka, A., Adelman, R. et al. Aflibercept in diabetic macular edema: evaluating efficacy as a primary and secondary therapeutic option. Eye 31, 342–345 (2017). https://doi.org/10.1038/eye.2016.233
Published:
Issue date:
DOI: https://doi.org/10.1038/eye.2016.233
This article is cited by
-
Functional and structural characteristics in patients with diabetic macular oedema after switching from ranibizumab to aflibercept treatment. Three year results in real world settings
International Journal of Retina and Vitreous (2022)
-
Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment
Graefe's Archive for Clinical and Experimental Ophthalmology (2018)
